|
1 Repertoire in Innate Immunity |
|
|
1 | (36) |
|
1.1 Historical Expansion of Defense System |
|
|
1 | (2) |
|
1.2 Columbus Era to Modern Revolution in Immunological Defense System |
|
|
3 | (2) |
|
1.3 Historical Profile of Defense Constituents and Progress in Innate Immune Repertoire |
|
|
5 | (19) |
|
|
|
5 | (1) |
|
|
|
5 | (3) |
|
|
|
8 | (1) |
|
|
|
8 | (1) |
|
1.3.5 Monocytes and Macrophages |
|
|
9 | (2) |
|
|
|
11 | (2) |
|
|
|
13 | (5) |
|
|
|
18 | (1) |
|
1.3.9 Lysozyme and Salvarsan |
|
|
19 | (2) |
|
1.3.10 Progress in Innate Immune Response Since Historic Spanish Flu |
|
|
21 | (3) |
|
1.4 The Outline of Innate Immunity |
|
|
24 | (6) |
|
1.4.1 Concept of Immune Receptors |
|
|
25 | (3) |
|
1.4.2 Host Protection from Microbial Invaders of Innate Immunity |
|
|
28 | (2) |
|
1.5 Autophagy from Microbial Invaders and Self-Associated Molecular Patterns (SAMPs) of Innate Immune Cells |
|
|
30 | (1) |
|
|
|
31 | (6) |
|
2 Dendritic Cells (DCs) in Innate Immunity |
|
|
37 | (16) |
|
2.1 General Biology of DCs |
|
|
37 | (3) |
|
2.2 Classification and Different Function of DCs |
|
|
40 | (9) |
|
2.2.1 pDC, Lymphoid Organ CD8α+ DC, and Tissue CD 103+DC Interaction with Tregs |
|
|
43 | (1) |
|
2.2.2 DCs Induce Tolerance State |
|
|
44 | (1) |
|
2.2.3 DC co-Stimulatory Receptors |
|
|
45 | (3) |
|
2.2.4 Application of DCs to Human Diseases |
|
|
48 | (1) |
|
|
|
49 | (4) |
|
3 Glycan Biosynthesis in Eukaryotes |
|
|
53 | (62) |
|
3.1 General Glycosylation Events |
|
|
54 | (2) |
|
3.2 Sugar Nucleotide Transporters Deliver Donor Saccharides to ER-Golgi Network |
|
|
56 | (2) |
|
|
|
58 | (2) |
|
|
|
60 | (1) |
|
3.5 O-glycosylation and Multiple O-Glycan Structures |
|
|
61 | (3) |
|
3.5.1 7 Core O-glycan Structures |
|
|
61 | (2) |
|
3.5.2 Modification of 7 Core O-Glycan Structures |
|
|
63 | (1) |
|
3.6 O-GlcNAcylation, O-Mannosylation, O-β-Glucosylation, O-α-Fucosylation, O-β-Glucosylation, O-β-Galactosylation, C-Glycosylation, and C-Mannosylation |
|
|
64 | (4) |
|
|
|
64 | (1) |
|
|
|
64 | (1) |
|
|
|
65 | (1) |
|
|
|
65 | (1) |
|
|
|
66 | (1) |
|
3.6.6 O-β-Galactosylation |
|
|
67 | (1) |
|
3.6.7 C-Mannosylation and C-Glycosylation |
|
|
67 | (1) |
|
3.7 Function of O-Glycosylation and O-Glycans |
|
|
68 | (1) |
|
3.8 Glycosaminoglycans (GAGs) |
|
|
69 | (20) |
|
3.8.1 Classification and Biosynthesis of GAGs |
|
|
70 | (1) |
|
3.8.2 Chondroitin Sulfate (CS) |
|
|
71 | (10) |
|
3.8.3 Dermatan Sulfate (DS) |
|
|
81 | (3) |
|
3.8.4 Keratan Sulfate (KS) |
|
|
84 | (1) |
|
3.8.5 Heparin and Heparan Sulfate |
|
|
85 | (1) |
|
3.8.6 Hyaluronic Acid (HA) or Hyaluronan |
|
|
86 | (1) |
|
3.8.7 Proteoglycans (PGs) |
|
|
86 | (2) |
|
|
|
88 | (1) |
|
3.9 Glycosylphosphatidylinositols (GPIs) Anchor Glycosylation |
|
|
89 | (14) |
|
3.9.1 General Structure of GPI Anchors |
|
|
89 | (2) |
|
3.9.2 Function of GPI-Anchored Protein |
|
|
91 | (4) |
|
3.9.3 Biosynthesis, Structural Assembly, and Transportation of GPI-Anchored Protein |
|
|
95 | (2) |
|
|
|
97 | (2) |
|
3.9.5 GPI Interaction with TLRs in Malaria P. falciparum |
|
|
99 | (4) |
|
3.9.6 GPI-Defected Disorders of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Prion Disease |
|
|
103 | (1) |
|
|
|
103 | (12) |
|
4 Glycans in Glycoimmunology |
|
|
115 | (84) |
|
4.1 Glycans in Cell Recognition and Evolutionary Adaptation in Organisms |
|
|
115 | (1) |
|
4.2 Changes in Glycan Structure Involved in Coregulated Expression of Glycan-Binding Lectin Counterparts |
|
|
116 | (1) |
|
4.3 Evolution of Lectin: Alternative Splicing Contributes to Variation for Glycan-Binding Receptors |
|
|
117 | (1) |
|
4.4 E-Selectin-Binding Ligand sLex (CD15s) on Neutrophil CD44 N-glycan and Alternatively Spliced Exon 6 Contains Core 2 O-Glycan sLea (CD44v6) Epitope |
|
|
118 | (1) |
|
4.5 Glycans Regulate T Cells |
|
|
119 | (17) |
|
4.5.1 Glycans Regulate Development and Differentiation in T Cells |
|
|
121 | (3) |
|
4.5.2 Glycosylation of Notch Receptor Signaling for Thymocyte β Selection and T Cell Function Regulation |
|
|
124 | (1) |
|
4.5.3 Alternatively Spliced Variants Produce Different Glycan Structures of CD43 and CD45 Isoforms in T Cells |
|
|
125 | (3) |
|
4.5.4 T Cells CD43 and CD45 Interaction with Their Counter-Receptor or Lectins to Determine T Cell Fates |
|
|
128 | (2) |
|
4.5.5 TCR Glycosylation Governs Hyper-response and Autoimmune Responses in T Cells and Tregs |
|
|
130 | (2) |
|
4.5.6 SAMP and N-Glycan-Dependent Modulation of Inhibitory T Cell Receptors to Suppress T Cell Functions |
|
|
132 | (2) |
|
4.5.7 Galectins in Suppression of T Cell Functions |
|
|
134 | (1) |
|
4.5.8 Glycans Regulate T Cell-Mediated Immune Suppression and Tolerance in Tumor Progression |
|
|
135 | (1) |
|
4.6 Abnormal N-Glycosylation in Autoimmunity |
|
|
136 | (1) |
|
4.7 Glycan Regulation of NK Cell Receptors |
|
|
137 | (8) |
|
|
|
138 | (1) |
|
|
|
139 | (2) |
|
4.7.3 Interaction of NCRs Ligands with Pathogens |
|
|
141 | (1) |
|
4.7.4 Interaction of NCRs Ligands with Self-Ligands |
|
|
142 | (1) |
|
4.7.5 NK Cells MHC-I-Independent Inhibitory Receptors Siglec-7 and Siglec-9 |
|
|
143 | (2) |
|
4.8 Carbohydrate Recognition of Target Antigens by DCs During Infection and Inflammation |
|
|
145 | (7) |
|
4.8.1 Lewis Ligand Recognition by DCs |
|
|
146 | (3) |
|
4.8.2 VIM Ceramide Dodecasaccharide |
|
|
149 | (3) |
|
4.9 Glycan-Specific Trafficking Receptors in DC Maturation |
|
|
152 | (2) |
|
4.10 Glycan Ligands in Trafficking of DC Migration |
|
|
154 | (4) |
|
4.10.1 sLex-PSGL-1 Glycans in DC Trafficking |
|
|
154 | (2) |
|
4.10.2 Ganglioside Recognition by DC Receptors in Trafficking |
|
|
156 | (2) |
|
4.11 Chemokine Receptors in DC Trafficking |
|
|
158 | (6) |
|
|
|
158 | (1) |
|
4.11.2 Chemokine Receptor |
|
|
159 | (1) |
|
4.11.3 Chemokine-GAG Interaction as a Type of Protein-Glycan Interactions |
|
|
159 | (1) |
|
4.11.4 Molecular Motifs in Chemokine for GAG Recognition |
|
|
160 | (2) |
|
4.11.5 C-C Type Chemokine Receptor 4 (CCR4) and Specific Ligand 17 (CCL17) and Specific Ligand 22 (CCL22) |
|
|
162 | (2) |
|
4.12 Glycan Structure-Recognizing Selectins in DC-Endothelium Interaction During Infection and Inflammation |
|
|
164 | (11) |
|
4.12.1 3 Species of Selectins: E-, L-, and P-selectins |
|
|
165 | (3) |
|
4.12.2 Representative Selectin Ligand PSGL-1 and Role of PSGL-1 O-Glycan |
|
|
168 | (1) |
|
4.12.3 Glycosyltransferases for Biosynthesis of PSGL-1 O-Glycan |
|
|
169 | (2) |
|
4.12.4 Designation of Carbohydrate Glycomimetic Drugs and Natural Inhibitors of Selectins |
|
|
171 | (1) |
|
4.12.5 Glycomimetic Drug Candidates |
|
|
172 | (2) |
|
4.12.6 GAG-Glycomimetic Drugs |
|
|
174 | (1) |
|
|
|
175 | (24) |
|
5 Pathogen-Host Infection Via Glycan Recognition and Interaction |
|
|
199 | (62) |
|
5.1 Lectin Recognition of Glycans on Cell Surface and Soluble Glycans |
|
|
199 | (5) |
|
5.2 Innate Immune-Specific and Host Defensing Lectins of Fungal, Protozoa, Invertebrate, and Lower Vertebrates |
|
|
204 | (2) |
|
5.3 How Do Hosts Interact with Pathogens? |
|
|
206 | (12) |
|
5.3.1 Lectin-Carbohydrate Interaction |
|
|
206 | (3) |
|
5.3.2 Bacterial Glycoconjugates Interact with Host Lectins |
|
|
209 | (9) |
|
5.4 Pathogen-Producing Lectins as Receptors to Bind to the Host Carbohydrates |
|
|
218 | (18) |
|
5.4.1 Uropathogenic E. coli (UPEC), Enterohemorrhagic E. coli (EHEC), and Enterotoxigenic E. coli (ETEC) |
|
|
220 | (8) |
|
5.4.2 Lectins and Glycans of Other Pathogenic Bacteria |
|
|
228 | (5) |
|
5.4.3 Viral Lectins or Host Lectin-Binding Glycans |
|
|
233 | (3) |
|
5.5 Host Lectin Defense Mechanisms in Lectin-Carbohydrate Interactions |
|
|
236 | (2) |
|
5.6 Pathogenic Glycans to Trigger Innate Immune Enhancement |
|
|
238 | (5) |
|
5.6.1 Example 1: Polysaccharides with Immune Enhancement of Cyrtomium macrophyllum |
|
|
240 | (1) |
|
5.6.2 Example 2: Activation of Macrophage by Polysaccharide from Paecilomyces cicadae |
|
|
240 | (1) |
|
5.6.3 Example 3: NK Cell-Mediated Cytotoxicity Increased by Arabinogalactan from Anoectochilus formosanus |
|
|
241 | (1) |
|
5.6.4 Example 4: Streptococcus pneumonia Polysaccharides Activate NK Cells, NK-Like T Cells, and Monocytes |
|
|
242 | (1) |
|
5.6.5 Example 5: C. macrophyllum Polysaccharides (CMP) Enhance Lymphocyte Proliferation and Macrophage Function |
|
|
242 | (1) |
|
5.7 TLR4 Receptor-Activating Glycans Activate NO Production in Macrophage |
|
|
243 | (1) |
|
5.8 CBPs or GBPs in Antigen Recognition |
|
|
244 | (1) |
|
|
|
245 | (16) |
|
6 Innate Immunity Via Glycan-Binding Lectin Receptors |
|
|
261 | (50) |
|
6.1 Glycosylation Effect on Autoimmunity and Inflammation |
|
|
262 | (4) |
|
6.1.1 Glycosylation in Immunological Recognition and Inflammation |
|
|
262 | (1) |
|
6.1.2 Glycosylation Effect on Autoimmunity |
|
|
263 | (3) |
|
6.2 Glycosylation Effect on Tumor Immunity of Immune Cells |
|
|
266 | (2) |
|
6.3 Immune Tolerance and Defense Mechanisms of Innate Immune DCs During Infection |
|
|
268 | (2) |
|
6.4 How Are Pathogenic Bacteria Recognized by Receptors of DCs of the Host Immune System? |
|
|
270 | (22) |
|
6.4.1 DC Lectins for Glycan Recognition of Invasive Agents |
|
|
270 | (3) |
|
6.4.2 Toll-Like Receptors |
|
|
273 | (5) |
|
6.4.3 Innate Immune Receptors in Malaria Infection |
|
|
278 | (9) |
|
6.4.4 Innate Immunity Receptors in Protozoan Parasite Toxoplasma gondii |
|
|
287 | (5) |
|
6.5 Pathogen Recognition and Adaptive Immune Responses in Acquired Immunity |
|
|
292 | (3) |
|
6.6 Galactose-Specific C-Type Lectin: Two Major ASGPR and Macrophage Galactose Lectin (MGL) in the Human |
|
|
295 | (2) |
|
|
|
297 | (14) |
|
7 Sialic Acid-Binding Ig-Like Lectins (Siglecs) |
|
|
311 | (186) |
|
7.1 PolySia and Host Sialic Acids Modulate Host Immune Responses as Pathogenic Decoys |
|
|
313 | (3) |
|
7.2 Sialic Acid Recognition by Siglecs for Self-or Nonself-Antigens |
|
|
316 | (2) |
|
7.3 Classification of Siglecs |
|
|
318 | (3) |
|
7.4 Evolution of Siglecs, Sialic Acids, and Sialic Acid O-Acetylation as Host Ligands (Receptors) for Microbes and Innate Immunity |
|
|
321 | (1) |
|
7.5 Microbial Sialic Acid-like Molecules Synthesis and Recognition of Microbial Sialic Acids by DCs and Bacteriophages |
|
|
322 | (3) |
|
7.6 Hematopoietic System in Siglecs |
|
|
325 | (2) |
|
|
|
327 | (7) |
|
7.7.1 Cytoplasmic ITIM and IT AM Domains of Siglecs |
|
|
327 | (2) |
|
7.7.2 Adaptor Proteins Associated with Siglecs |
|
|
329 | (1) |
|
7.7.3 SA-Recognition Tropism of Siglecs |
|
|
330 | (4) |
|
7.8 Inhibitory Signaling of DCs |
|
|
334 | (4) |
|
7.9 Siglec-1 (CD169, Sialoadhesin/Sn) |
|
|
338 | (8) |
|
7.9.1 General SAbinding Specificity of Siglec-1 |
|
|
338 | (3) |
|
7.9.2 Siglec-1 Is a Pathogen-Binding Receptor |
|
|
341 | (2) |
|
7.9.3 Siglec-1 Recognizes HIV and Is a Transinfection Receptor Expressed on mDCs |
|
|
343 | (3) |
|
|
|
346 | (20) |
|
7.10.1 General and Structural Aspects of CD22/Siglec-2 |
|
|
346 | (3) |
|
7.10.2 CD22 I Associated with Development of Autoimmune Diseases |
|
|
349 | (2) |
|
7.10.3 CD22 Function in Immune Tolerance Events |
|
|
351 | (3) |
|
7.10.4 Role of CD22 (Siglec-2, Mice Siglec-G) in Immune Responses |
|
|
354 | (3) |
|
7.10.5 Model Ligands for Recognition of CD22 on B Cells |
|
|
357 | (1) |
|
7.10.6 B Cell-Targeted Immunotherapy Through CD22-Positive Targeting of B-Cell Lymphomas |
|
|
357 | (2) |
|
7.10.7 Immune Tolerance Capacity of Neu5Ac-α2,6-Gal Ligands in DCs by ST6Gal-l of Tumor Cells for Immunesurveillance |
|
|
359 | (1) |
|
7.10.8 CD22 Vs. Pathogens |
|
|
360 | (1) |
|
7.10.9 CD22 Application with CAR-T on Acute Lymphoblastic Leukemia (ALL) |
|
|
361 | (1) |
|
7.10.10 CD22/Siglec-2 Coreceptor, CD45 on T Cells |
|
|
362 | (4) |
|
7.11 Siglec-4/Myelin-Associated Glycoprotein (MAG) |
|
|
366 | (4) |
|
7.11.1 General Aspects of MAG/Siglec-4 |
|
|
366 | (1) |
|
7.11.2 Siglec-4/MAG in the CNS and Brain Development |
|
|
367 | (2) |
|
7.11.3 Siglec-4/MAG in Hippocampal Long-Term Potentiation |
|
|
369 | (1) |
|
7.12 Siglec-15, Non-CD33-Related Siglecs in Humans |
|
|
370 | (3) |
|
7.12.1 The Structure and Expression of Siglec-15, Called Misnomer "CD33L3" in Humans |
|
|
370 | (2) |
|
7.12.2 DAP12-Syk Pathway in Siglec-15-Mediated Remodeling of the Tumor Microenvironment |
|
|
372 | (1) |
|
7.12.3 Siglec-15 Functions in Osteoclastogenesis |
|
|
372 | (1) |
|
7.13 Siglec-3 (CD33)-Related Siglecs on DCs |
|
|
373 | (74) |
|
|
|
374 | (1) |
|
7.13.2 Structure, Natural Ligand, and Cellular Signaling with SHP-1/-2 of Siglec-3/CD33 |
|
|
375 | (2) |
|
7.13.3 Pathogen Ligand for CD33 |
|
|
377 | (1) |
|
7.13.4 Siglec-3/CD33 Is Related to SOCS3 and Internalization of CD33 |
|
|
378 | (1) |
|
7.13.5 Putative Functions of Siglec-3/CD33 in Alzheimer's Disease (AD) |
|
|
379 | (2) |
|
7.13.6 Siglec-3-/CD33-Based Immunotherapy for AML |
|
|
381 | (1) |
|
7.13.7 Siglec-5/CD170 as a CD33-Related Siglec |
|
|
382 | (6) |
|
7.13.8 Siglec-6 as a CD33-Related Siglec |
|
|
388 | (2) |
|
7.13.9 Siglec-7 (CD328) as a CD33-Related Siglec |
|
|
390 | (9) |
|
7.13.10 Siglec-8 as a CD33-Related Siglec and Siglec-F as a Mouse Paralog |
|
|
399 | (4) |
|
7.13.11 Siglec-9 as a CD33-Related Siglec and Murine Functional Counterpart, Siglec-E |
|
|
403 | (21) |
|
7.13.12 Siglec-10 (Mouse Ortholog Siglec-G) in Humans as a CD33-Related Siglec |
|
|
424 | (9) |
|
7.13.13 Human Siglec-11 as a CD33-Related Siglec |
|
|
433 | (5) |
|
7.13.14 Siglec-14 in Humans as a CD33-Related Siglec |
|
|
438 | (7) |
|
7.13.15 Siglec-16 as a CD33-Related Siglec Is a Paired Receptor with Siglec-11 |
|
|
445 | (2) |
|
7.14 Mouse CD33-Related Siglecs with ITIM-Like Domains |
|
|
447 | (12) |
|
7.14.1 mSiglec-E that Belongs to CD33-Related Siglecs |
|
|
448 | (3) |
|
7.14.2 Siglec-F (Human Paralog Siglec-8) as a CD33-Related Siglec |
|
|
451 | (3) |
|
7.14.3 Human Siglec-10 and Mouse Ortholog Siglec-G as CD33-Related Siglecs |
|
|
454 | (3) |
|
7.14.4 Siglec-H as a CD33-Related Siglec |
|
|
457 | (2) |
|
|
|
459 | (38) |
|
8 C-Type Lectin (C-Type Lectin Receptor) |
|
|
497 | (60) |
|
8.1 Evolutionary Diversity of C-Type Lectins |
|
|
497 | (2) |
|
8.2 Ca2+-Dependent Glycan-Binding CTLs |
|
|
499 | (3) |
|
8.3 Myeloid CTL-Like Receptor or Myeloid-Suppressive or Inhibitory CLR (MICL), CLEC 12A |
|
|
502 | (2) |
|
8.4 Macrophage Inducible CTLR (Mincle, Clec4e, ClecSf9)/Macrophage CTL (MCL, CLEC4d, ClecSfS) |
|
|
504 | (6) |
|
8.4.1 Expression and Ligand-Binding Specificity of Mincle, Clec4e, ClecSf9, and MCL |
|
|
504 | (1) |
|
8.4.2 Pathogenic PAMPs-Recognition of Mincle and MCL |
|
|
505 | (2) |
|
8.4.3 Thl/Thl7 Activation and T Cell Development in Mincle or MCL Interaction with Host |
|
|
507 | (3) |
|
8.5 Mannose Receptor (MR) as CLR and Macrophage Mannose Receptor |
|
|
510 | (5) |
|
8.5.1 Structural Basis and Functions of MR |
|
|
510 | (2) |
|
8.5.2 MR Expression in Immune Systems and Interaction with Helminth Flatworm Trematodes |
|
|
512 | (2) |
|
8.5.3 Recognition of Pathogenic Microbes by MR |
|
|
514 | (1) |
|
8.6 Mannose (or Mannan)-Binding Protein (MBP) and Mannose-Binding Lectin (MBL) |
|
|
515 | (5) |
|
8.6.1 Structural Basis and Glycan Ligand Binding Specificity of MBL |
|
|
516 | (1) |
|
8.6.2 Immunoprotective Activity of MBL |
|
|
517 | (2) |
|
8.6.3 MBL Function in Diseases |
|
|
519 | (1) |
|
8.7 Fucose-Binding Lectin (FBL) and Ficolin |
|
|
520 | (6) |
|
8.7.1 Fucose-Binding Lectin (FBL) Diversity of F-Lectin Repertoires |
|
|
520 | (1) |
|
8.7.2 Specificity of Ficolins or FBL |
|
|
521 | (2) |
|
8.7.3 Ficolin Functions in the Immune Response |
|
|
523 | (2) |
|
8.7.4 Ficolin Interaction with Microorganisms |
|
|
525 | (1) |
|
8.8 Dectin 1 (CLEC-7A in Human) |
|
|
526 | (7) |
|
8.8.1 Basic Function and Structure of Dectin 1 |
|
|
526 | (1) |
|
8.8.2 Dectin-1 Recognizes β1,3/β1,6-glycans in Fungi, Plants, Bacteria, and House Dust Mite |
|
|
527 | (3) |
|
8.8.3 Dectin-1 Cluster Includes CTL-Like Receptor 2 (CLEC-2) |
|
|
530 | (1) |
|
8.8.4 CLEC Structures and Ligand Recognition |
|
|
531 | (2) |
|
8.9 DC-Associated CTL-2 (Dectin-2) Family or CLEC4n |
|
|
533 | (4) |
|
8.9.1 Structural Basis and Function of Dectin-2 |
|
|
533 | (2) |
|
8.9.2 Langerhans Cell-Specific Expression of Dectin-2 and Interaction with Fungal High-Man Glycans |
|
|
535 | (2) |
|
8.10 Dectin-3 (Clec4D, Clecsf8, MCL, Macrophage CTL) |
|
|
537 | (3) |
|
|
|
540 | (17) |
|
|
|
557 | (28) |
|
9.1 General and Structural Aspects of Galectins |
|
|
557 | (9) |
|
9.1.1 Biological Roles of Galectins |
|
|
558 | (1) |
|
9.1.2 Immunological Roles of Galectins |
|
|
559 | (2) |
|
9.1.3 Classification of Galectins |
|
|
561 | (3) |
|
9.1.4 Galectin Ligands in Proteins and Gangliosides |
|
|
564 | (1) |
|
9.1.5 Galectins in Lower Organisms such as Zebrafish or Marine Oyster |
|
|
565 | (1) |
|
|
|
566 | (1) |
|
9.3 Galectin-3 and - 8 Recognize GM3, But Not Galectin-4 |
|
|
567 | (3) |
|
|
|
567 | (3) |
|
|
|
570 | (1) |
|
9.4 Galectin-1 and - 4 Bind to GM1, But Not GM3 |
|
|
570 | (6) |
|
|
|
570 | (1) |
|
|
|
571 | (5) |
|
9.5 Galactine-9 and Galelctin-10 |
|
|
576 | (1) |
|
|
|
576 | (9) |
|
|
|
585 | (22) |
|
10.1 DC-Specific ICAM-3-Grabbing Non-integrin, DC-SIGNB (CD209) |
|
|
585 | (8) |
|
10.1.1 Molecular Characteristics of DC-SIGN |
|
|
585 | (1) |
|
10.1.2 General Signaling of DC-SIGN |
|
|
586 | (3) |
|
10.1.3 α2,6 Sialyl IgG Fc Function by DC-SIGN Receptor |
|
|
589 | (1) |
|
10.1.4 DC-SIGN Binds to Pathogens, Antigen, and Glycans |
|
|
590 | (1) |
|
10.1.5 DC-SIGN Role in DC-Mediated Viral Transmission by HIV-1 |
|
|
591 | (1) |
|
10.1.6 DC-Mediated Immunosuppression by Mycobacteria |
|
|
592 | (1) |
|
10.1.7 DC-SIGN Recognizes Lewis Antigens Expressed in PMN |
|
|
593 | (1) |
|
10.2 Other DCs-Derived Receptors |
|
|
593 | (9) |
|
10.2.1 Dendritic Cell NK Lectin Group Receptor (DNGR-1; CLEC9A) |
|
|
593 | (2) |
|
10.2.2 CTL-Like Receptor-1 (CLEC-1) |
|
|
595 | (2) |
|
10.2.3 CTL-Like Receptor, CLEC12A, Known as Myeloid Inhibitory CTL-Like Receptor (MICL), CTL-Like Molecule-1 (CLL-1), DC-Associated CTL 2 (DCAL-2), and CD371 |
|
|
597 | (3) |
|
|
|
600 | (2) |
|
|
|
602 | (5) |
|
11 Toll-Like Receptors (TLRs) |
|
|
607 | (24) |
|
11.1 TLR Molecular Structure, Subtypes, and Recognition Ligand |
|
|
609 | (3) |
|
11.2 Signal Initiation and Transduction of TLRs |
|
|
612 | (2) |
|
11.3 Glycosylation of TLRs |
|
|
614 | (1) |
|
11.4 General TLR Functions as Pathogen and Antigen Receptors on DCs |
|
|
614 | (2) |
|
11.5 TLR-9 as a CpG DNA Receptor |
|
|
616 | (1) |
|
11.6 TLR-3 as a dsRNA Receptor |
|
|
617 | (1) |
|
11.7 TLR-4 as the LPS Receptor |
|
|
618 | (4) |
|
11.7.1 Ligands of TRL4 Recognition |
|
|
619 | (2) |
|
11.7.2 MyD88-Dependent Pathway of TLR4 |
|
|
621 | (1) |
|
11.7.3 MyD88-Independent Pathway of TLR4 |
|
|
621 | (1) |
|
|
|
622 | (3) |
|
11.8.1 Three Major Domains and Binding Ligand of TLRll |
|
|
623 | (1) |
|
11.8.2 TLR 11 Intracellular Signal Transduction |
|
|
624 | (1) |
|
11.9 Inhibition of TLRs by Gangliosides |
|
|
625 | (1) |
|
|
|
626 | (5) |
|
12 CD33 and CD33-Related Siglecs in Pathogen Recognition and Endocytosis of DC in the Innate Immune System |
|
|
631 | |
|
|
|
631 | (5) |
|
12.1.1 General Biology of CD33 |
|
|
631 | (4) |
|
12.1.2 CD33 (Siglec-3)-Targeting of Acute Myeloid Leukemia (AML) |
|
|
635 | (1) |
|
12.1.3 CD33 (Siglec-3)-Targeting Treatment of Alzheimer's Disease (AD) |
|
|
636 | (1) |
|
12.2 CD33-Related Siglecs (CD33rSiglecs) |
|
|
636 | (3) |
|
12.2.1 Inhibitory CD33rSiglecs in Escape from Tumor and Bacterial Immunosurveillance |
|
|
637 | (1) |
|
12.2.2 Activating CD33rSiglecs |
|
|
638 | (1) |
|
12.3 Pathogenic Suppression of the Pathogen-Specific Host Immune Response |
|
|
639 | (9) |
|
12.3.1 Inhibitory Receptor CD200R and CD200: CD200R1 Signaling |
|
|
640 | (2) |
|
12.3.2 Pathogenic Decoy Ligands Neutralize Host Immunity Through Eliciting Host CD200-CD200R1 Inhibitory Signaling |
|
|
642 | (6) |
|
12.4 DCs Tumor Immunotherapy Through Sialyl Binding of DCsto T Cells |
|
|
648 | (2) |
|
|
|
650 | |
